【制药网 行业动态】近日,据多家媒体报道,武田制药全球高级副总裁、武田中国总裁单国洪即将离职,其下一站很有可能加入百济神州。若此次变动属实,无疑将在医药行业激起层层涟漪,引发广泛关注与讨论。公开资料显示,单国洪在武田中国的任期成绩斐然。自2017年9月掌舵武田中国以来,他凭借突出的领导才能与精准的市场策略,成功带着武田实现飞跃式发展,业绩也一路高歌猛进,成为武田全球版图中仅次于美国和日本的第三大...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.